SciTech Announces Equity Crowdfunding Campaign
---Now Closed---

(GROSSE POINTE FARMS, MI) March 15, 2022 – SciTech Development LLC, a specialty pharmaceutical company, is pleased to announce the launch of its equity crowdfunding campaign on StartEngine. SciTech plans to grow the company, scale-up clinical drug manufacturing, and to commence the company's first clinical trial of ST-001 nanoFenretinide for the treatment of non-Hodgkin’s lymphoma (NHL). Non-Hodgkin’s lymphomas are cancers that begin in the lymphatic system, which is part of the body's germ-fighting immune system.

​

            SciTech’s patented lead drug candidate ST-001 nanoFenretinide is a combination of the company’s proprietary drug delivery platform known as SDP, and fenretinide, a drug with a well-documented safety profile. SciTech is further pleased to announce that ST-001 has an FDA approved Investigational New Drug Application (IND) and Orphan Drug Designation (ODD) for two types of NHL: peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). ST-001 is ready to enter the clinic at Rush University Medical Center (RUMC) in Chicago, IL where it has IRB approval (Institutional Review Board).

​

            Earle Holsapple, President of SciTech Development, relays that FDA approval of ST-001 would be a significant step towards revenue generation, but more importantly, believes that SciTech's scientific breakthroughs will have a profound impact on patients who are battling cancer.

​

            Visit https://www.startengine.com/scitechdevelopment to invest in SciTech’s crowdfunding campaign, early investors qualify for time-based bonuses. For company, product, and investor information visit www.SciTechSDP.com. Detailed information regarding SciTech’s science and the company can be found at www.SciTechDevelopment.com.